胃癌HER-2表达与术后辅助化疗疗效的相关性分析  

Association between HER-2 expression and the efficacy of postoperative adjuvant chemotherapy in gastric carcinoma

作　　者：周易[1] 吕世杰[2] 王兰君[3] 范丽昕[1] 

机构地区：[1]大连市第三人民医院肿瘤内科,大连116031 [2]大连市妇产医院妇产科,大连116033 [3]大连市友谊医院神经内科,大连1161000

出　　处：《癌症进展》2016年第3期236-239,244,共5页Oncology Progress

摘　　要：目的通过总结胃癌术后辅助化疗病例及HER-2表达情况,探讨HER-2表达与胃癌术后辅助化疗疗效之间的相关性。方法回顾性分析185例胃癌术后辅助化疗患者资料,总结其病理特点、HER-2表达状况及无疾病进展生存(DFS)、总生存(OS),分析HER-2与临床病理特点及DFS、OS的关系。结果 185例胃癌患者中,HER-2阴性141例,阳性44例,阳性率24%。HER-2基因的扩增与肿瘤部位、肿瘤的分化程度及远处转移部位相关,与年龄、性别、分期无关;HER-2阳性组中位DFS为9.1个月,中位OS为15.1个月,HER-2阴性组中位DFS为15.2个月,中位OS为25.5个月,HER-2阴性的患者较HER-2阳性的患者更能从术后辅助化疗中获益(P=0.046),并且生存期更长(P=0.01)。结论 HER-2无扩增的患者可从术后辅助治疗中获益,DFS与OS均有延长。objective To analyze the patients with gastric carcinoma who received adjuvant chemotherapy after surgical resection, and to evaluate the correlation between the efficacy of adjuvant chemotherapy and HER-2 expression. Method 185 cases of gastric cancer that were administered with postoperative adjuvant chemotherapy were analyzed retrospectively. The clinicopathological features, HER-2 expression, disease-free survival （DFS）, overall survival （OS） were summarized, and the association between efficacy of adjuvant chemotherapy and HER-2 expression was investigated. Re- sult Of the 185 cases, 141 were HER-2 negative （-）, 44 were HER-2 positive （＋）, with a positive rate of 24%. The HER- 2 overexpression was closely related with tumor location, degree of differentiation and distant metastases, though no sig- nificant association with age, sex and TNM stage was observed. The DFS and median OS in the group of HER-2 （＋） were 9.1 months and 15.1 months, and were 15.2 months and 25.5 months in the group of HER-2（-） （P=0.046）, respectively. Patients with HER-2（-） may benefit more fiom postoperative adjuvant chemotherapy compared with those with HER-2 （＋）, and the OS is comparatively longer （P=0.01）. Conclusion Patients lacking HER-2 amplification may benefit from postoperative adjuvant chemotherapy with extended DFS and OS.

关 键 词：胃癌 术后辅助化疗 HER-2 无疾病进展生存 

分 类 号：R735.2[医药卫生—肿瘤]